The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen. - Wikidata - awgldk - TriplyDB

The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.

The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.

http://www.wikidata.org/entity/Q40607139

about

Interaction of TFAP2C with the estrogen receptor-alpha promoter is controlled by chromatin structure Circadian disruption and breast cancer: an epigenetic link?Specific activity of class II histone deacetylases in human breast cancer cells 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.Minireview: The versatile roles of lysine deacetylases in steroid receptor signaling Z-ligustilide restores tamoxifen sensitivity of ERa negative breast cancer cells by reversing MTA1/IFI16/HDACs complex mediated epigenetic repression of ERa ATM modulates transcription in response to histone deacetylase inhibition as part of its DNA damage response.Valproate activates bovine leukemia virus gene expression, triggers apoptosis, and induces leukemia/lymphoma regression in vivo.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells Bioactive dietary supplements reactivate ER expression in ER-negative breast cancer cells by active chromatin modifications Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies?Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor.Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs.Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.Histone deacetylase inhibitors and cancer therapy.ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors.HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma.A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer.Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.Tamoxifen Action in ER-Negative Breast Cancer.Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist.Epigenetic targeting in breast cancer: therapeutic impact and future direction.Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.Maternal regulation of estrogen receptor alpha methylation RETRACTED: Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential?Epigenetic modifications of the Estrogen receptor beta gene in epithelial ovarian cancer cells Aberrant promoter CpG methylation and its translational applications in breast cancer.The silent estrogen receptor--can we make it speak?Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance.New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.Activation of ERα signaling differentially modulates IFN-γ induced HLA-class II expression in breast cancer cells.A chimeric SERM-histone deacetylase inhibitor approach to breast cancer therapy.Modulation of gene expression in ovarian cancer by active and repressive histone marks.

P2860

Q24657263-77400169-8C78-4B81-9E20-5355FDDB9FA4 Q26798258-84D32E77-CEDD-469E-9D50-D9CB8825146D Q33606021-490B0A25-3CC4-4BD8-AD24-8BED81BB172F Q33612962-869E7C1A-DC75-46BB-93B2-0935E87B4FEE Q33632070-B1F764B4-02F3-4037-994D-93390F3A353C Q33710113-52CEB5C4-05F2-4005-979A-CCC0C29DD3A3 Q33751387-44252DE3-F69B-47A4-92DA-97F89FF7DC16 Q33900608-46168378-7168-4FB8-A4EC-0CF202FBE371 Q34147910-C35B5325-07CE-461D-A3CA-2FA691261A6D Q34258435-1FFF77C2-3FF8-4816-8DF7-CBF4782A23AD Q34291226-EDD70B6C-A742-45E0-9F03-91ECC2815F0E Q34417159-65DCF0AC-65CB-45F0-AE2E-F1EF924549FC Q34488424-4D774ED6-3446-4096-B289-D18DFDBED490 Q34994744-7556F8A7-7F61-412A-845A-F6CE48EDD51B Q34998421-584B727F-38EE-49AA-BF63-A6887F444D7B Q35034708-A2F79615-1CB2-46DE-A242-12D60D4566A0 Q35050840-C097AC26-BF21-4195-9A45-15ECB85F6E41 Q35201384-4DD8F336-73EA-40A1-AA58-A292393838DC Q35911749-2A87F566-D259-4348-9E0E-77964ED5D1CC Q36028669-C227213E-4282-4889-88F0-458F5A65570A Q36083466-3F7D080E-D14E-43C6-99D3-9210F671BB61 Q36099567-B24037BD-A0CA-4498-909C-B1DA17927B36 Q36528653-F75D8BE3-DEFC-4A40-AE76-A430AB3E7D2E Q36579794-39FD7C87-962B-4D5B-9D27-CA3C14403079 Q36624258-545C2624-1401-4E96-87D7-76D2D0584486 Q36688302-A48A98F4-9D74-4DEF-8FB9-3FC78FC2754D Q36718441-FF6E6361-4628-43AD-ADEE-4411253D99BA Q36856318-DF99B736-282F-4419-ADEF-4A08C10F3CDA Q36996317-9577AE61-5B27-44C8-B25E-7C8EE7841CDB Q37032750-4873F4BB-87F7-403E-AF44-28DC578E9F5C Q37129445-EFB5E193-9EB3-408B-AA96-406EEC346DCE Q37252722-1B995242-0F10-4F3E-8C53-9F9640F89936 Q37332214-FBFFE3DE-0426-4E01-BD12-4FC86868483E Q37354053-950863FE-FAD4-4F70-99C9-82141F97EFAA Q37468213-077ED4E7-D949-4D54-AA65-C0DAEECC13D0 Q37472631-D448BFF1-A479-4C66-B48D-49818A80BF71 Q37503780-BD696181-DD8F-4B67-98D5-16F8126CE3A5 Q37521175-706AE354-A365-46BB-9364-A8C77F1FA2D4 Q37656483-E44C074A-0E83-4807-A584-020D17BA197F Q37962015-379527FB-1635-41C4-B8A0-9159A8D5EEDF

P2860

The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.

http://www.wikidata.org/entity/Q40607139

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

The histone deacetylase inhibi ...... ast cancer cells to tamoxifen.

@en

type

label

The histone deacetylase inhibi ...... ast cancer cells to tamoxifen.

@en

prefLabel

The histone deacetylase inhibi ...... ast cancer cells to tamoxifen.

@en

P1433

Q40607139-5B573525-06F5-4DCD-814F-9E09776266FD

P1476

Q40607139-BA1DE94E-4A51-4D7A-ABF7-23D31C7DEA86

P2093

Q40607139-2D3A0800-F783-45A9-A11B-2368B1B155E6

Q40607139-3B352A49-CF88-4395-A356-CD3EFA8BE652

Q40607139-3E999FB8-1488-45A6-A9EE-B4CAB07CA06D

Q40607139-53ADAE77-04EA-4AC1-9A5C-F10DC917CDA3

Q40607139-A52B73BA-434A-4B0B-812B-908CFBA296CA

Q40607139-A64826DD-6C85-4132-85B9-97685F3B95A6

Q40607139-D5F00E45-D112-4BB1-8D57-FBFE15B5DABD

P2860

Q40607139-215B9111-8FB5-4B1B-9882-761F3F111649

Q40607139-2F8C145A-454E-4B00-9FA1-D130750CD498

Q40607139-35D80309-1487-44B0-B20E-46956AC28DE6

Q40607139-6A204043-96DE-4A21-A11B-971207053407

Q40607139-764D43C4-7C89-44B5-853D-FB6E24566080

Q40607139-ADE41DEE-A9CF-47D8-B777-B3332B7004DB

Q40607139-DAD3C413-DCB8-4F90-ABD0-11F48E864F10

Q40607139-E7FE1418-8403-4F81-B363-CD40581D78B7

Q40607139-FEF6B1D1-664A-4B3D-B2A8-BF32B759E4F6

P2888

Q40607139-E3B69E71-4496-48C2-AE34-890540E9029E

P304

Q40607139-C35F49F6-EB64-4F92-AD0C-4A26FA3A2256

P31

Q40607139-F0A1C461-05A4-4448-8CF6-0DE54DD8A088

P356

Q40607139-77768EE8-37A4-43A5-944E-A7FAED2E5BB9

P407

Q40607139-DC7C8E2C-A451-459E-8A00-2BD2AAF93E19

P433

Q40607139-DBD64E9F-A2C9-44FD-A4E8-8FF0CBBC5A55

P478

Q40607139-EBF3F780-D099-49D1-8ED1-CCE082185452

P577

Q40607139-31A8C5C0-CD56-4129-BB53-5DEA5C178D4A

P5875

Q40607139-5DD93B05-1C2A-4C58-A793-89FC312DAE46

P6179

Q40607139-04604E9B-6854-4A49-9DC0-A411D196F4F2

P698

Q40607139-B44DB5E8-64F0-400C-A299-5DA0CB6F9168

P356

P1433

P1476

The histone deacetylase inhibi ...... ast cancer cells to tamoxifen.

@en

P2093

Eun Ryoung Jang

http://www.w3.org/2001/XMLSchema#string

Eun Sook Lee

http://www.w3.org/2001/XMLSchema#string

Gajin Jeong

http://www.w3.org/2001/XMLSchema#string

Jong-Soo Lee

http://www.w3.org/2001/XMLSchema#string

Soo-Jeong Lim

http://www.w3.org/2001/XMLSchema#string

Tae-You Kim

http://www.w3.org/2001/XMLSchema#string

Yung-Jue Bang

http://www.w3.org/2001/XMLSchema#string

P2860

An endocrine pathway in the prostate, ERbeta, AR, 5alpha-androstane-3beta,17beta-diol, and CYP7B1, regulates prostate growth

Trafficking of nuclear receptors in living cells.

Estrogen receptors and proliferation markers in primary and recurrent breast cancer

Estrogen receptor beta in breast cancer.

Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators.

Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2-M transition.

A new interpretation of antiestrogen action.

Agonist-dependent repression mediated by mutant estrogen receptor alpha that lacks the activation function 2 core domain.

Effect of estradiol on histone acetylation dynamics in human breast cancer cells.

P2888

P304

1724-1736

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.ONC.1207315

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8958076

http://www.w3.org/2001/XMLSchema#string

P6179

1026102020

http://www.w3.org/2001/XMLSchema#string

P698

14676837

http://www.w3.org/2001/XMLSchema#string